By: Anna Brown
Fujifilm Biotechnologies CEO Lars Petersen says CDMOs must expand modalities, embrace AI, and boost biosimilar capacity amid biopharma's $300B patent cliff.


Anna Brown is a news reporter at Endpoints News. She focuses on the manufacturing side of the biopharma industry, covering topics such as pharmaceutical manufacturing, regulation, and healthcare administration, while also running the weekly Endpoints manufacturing newsletter. Anna's work has been featured in various outlets, including WCNC Charlotte, Pew Research Center, and Yahoo News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
Anna's coverage primarily focuses on press releases and announcements in the manufacturing and healthcare industries. She would likely respond well to pitches that provide insights into new developments, partnerships, or investments within pharmaceutical companies, as well as changes in regulatory policies affecting the industry.
Given her focus on private sector and government announcements related to healthcare and pharmaceutical manufacturing, Anna may be interested in commentary from industry insiders with detailed knowledge of specific deals or regulatory changes. Pitches highlighting unique perspectives on how these developments could impact the broader market might also resonate with her.
It is evident that Anna does not have a specific geographical focus but rather covers international news within the healthcare and pharmaceutical industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .